Table 1.

Characteristics of patients and transplants

Variables	Totaln = 166	Hepcidin‐25, <35 ng/mLn = 83	Hepcidin‐25, ≥35 ng/mLn = 83	P value
Age at transplant (years)
Median (range)	49.5 (17–66)	47 (17–65)	51 (19–66)	0.22
Sex
Male	92	48	44	0.64
Female	74	35	39
Disease
Myeloid malignancies	103	49	54	0.52
Lymphoid malignancies	63	34	29
Risk of disease
Standard	100	53	47	0.43
High	66	30	36
Source of stem cells
HLA‐matched related	31	18	13	0.66
HLA‐mismatched related	13	5	8
Unrelated BM or PBa	75	38	37
Unrelated CB	47	22	25
ABO blood‐type matching
Matched	67	32	35	0.75
Mismatched	99	51	48
Conditioning regimen
Myeloablative intensity	79	45	34	0.12
Reduced intensity	87	38	49
GVHD prophylaxis
Tacrolimus‐based	143	68	75	0.18
Cyclosporine‐based	23	15	8

^aAmong the stem cell sources from unrelated donors, all but 1 were BM.

Patient and transplant characteristics between two groups were compared using the Mann–Whitney U‐test or Fisher's exact test, as appropriate. HLA, human leukocyte antigen; BM, bone marrow; PB, peripheral blood; CB, cord blood; GVHD, graft‐versus‐host disease; tacrolimus‐based, tacrolimus with or without other agents; cyclosporine‐based, cyclosporine with or without other agents.